Acute asthma, salbutamol and hyperglycaemia

Area of Science:

• Pediatric Pulmonology
• Clinical Pharmacology
• Pediatric Endocrinology

Background:

• Acute severe asthma is a common pediatric respiratory emergency.
• Salbutamol is a standard bronchodilator, but its metabolic effects require consideration.
• Understanding drug-induced metabolic changes is crucial for patient management.

Purpose of the Study:

• To investigate the impact of frequent, high-dose nebulized salbutamol on plasma glucose levels in children.
• To determine if salbutamol administration can induce hyperglycemia in pediatric patients with severe asthma.

Main Methods:

• A cohort of 12 children with acute severe asthma (mean age 60 months) received frequent high-dose nebulized salbutamol.
• Plasma glucose concentrations were monitored to assess changes from baseline.
• Statistical analysis compared initial glucose levels with peak levels post-treatment.

Main Results:

• A statistically significant increase in plasma glucose concentrations was observed.
• Mean initial glucose levels differed significantly from peak glucose levels after salbutamol administration.
• The findings indicate a direct correlation between nebulized salbutamol and elevated glucose.

Conclusions:

• Nebulized salbutamol, particularly at high doses and frequent intervals, can induce hyperglycemia in children with acute severe asthma.
• Clinicians should be aware of this potential side effect and monitor glucose levels in pediatric patients.
• Further research may explore the clinical significance and management of salbutamol-induced hyperglycemia in this population.